Tigecycline - Trillium Therapeutics

Drug Profile

Tigecycline - Trillium Therapeutics

Latest Information Update: 22 May 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator University Health Network
  • Developer Memorial Sloan-Kettering Cancer Center; Princess Margaret Hospital (University of Toronto); University Health Network; University of California at Los Angeles; University of Kansas
  • Class Antibacterials; Glycylcyclines; Small molecules
  • Mechanism of Action Mitochondrial protein inhibitors; Protein 30S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Acute myeloid leukaemia

Most Recent Events

  • 07 Aug 2014 Discontinued - Phase-I for Acute myeloid leukaemia in Canada (IV)
  • 07 Aug 2014 Discontinued - Phase-I for Acute myeloid leukaemia in USA (IV)
  • 02 Jun 2014 Stem Therapeutics changes its name to Trillium Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top